

# ISO/TR 12417-2:2022-07 (E)

## Cardiovascular implants and extracorporeal systems - Vascular device-drug combination products - Part 2: Local regulatory information

---

<b>Contents</b>		<b>Page</b>
Foreword .....		v
Introduction .....		vi
1	Scope .....	1
2	Normative references .....	1
3	Terms and definitions .....	1
4	Information on device- and drug-related aspects -- Applicable documents for local guidance .....	4
4.1	General .....	4
4.2	Australia .....	4
4.2.1	General .....	4
4.2.2	Australia: Managing changes .....	5
4.2.3	Australia: Clinical evaluation requirements .....	5
4.2.4	Australia: Audit requirements .....	5
4.3	Brazil .....	5
4.3.1	Brazil: Managing changes .....	5
4.3.2	Brazil: Clinical evaluation requirements .....	6
4.3.3	Brazil: Audit requirements .....	6
4.4	Canada .....	6
4.4.1	Canada: Managing changes .....	6
4.4.2	Canada: Clinical evaluation requirements .....	6
4.4.3	Canada: Audit requirements .....	6
4.5	European Union (EU) .....	6
4.5.1	EU: Managing changes .....	6
4.5.2	EU: Material inclusion and labelling requirements .....	7
4.5.3	EU: Clinical evaluation requirements .....	7
4.5.4	EU: Audit requirements .....	7
4.6	India .....	7
4.6.1	India: Managing changes .....	7
4.6.2	India: Clinical evaluation requirements .....	8
4.6.3	India: Audit requirements .....	8
4.7	Japan .....	8
4.7.1	Japan: Managing changes .....	8
4.7.2	Japan: Clinical evaluation requirements .....	8
4.7.3	Japan: Audit requirements .....	8
4.8	People's Republic of China (PRC) .....	8
4.8.1	PRC: Managing changes .....	8
4.8.2	PRC: Clinical evaluation requirements .....	9
4.8.3	PRC: Audit requirements .....	10
4.9	Russia .....	10
4.9.1	Russia: Managing changes .....	10
4.9.2	Russia: Clinical evaluation requirements .....	10
4.9.3	Russia: Audit requirements .....	10
4.10	United States of America (USA) .....	10
4.10.1	USA: Managing changes .....	10
4.10.2	USA: Clinical evaluation requirements .....	11
4.10.3	USA: Audit requirements .....	11

<b>5</b>	<b>Managing changes that can impact the DCP .....</b>	<b>12</b>
<b>5.1</b>	<b>General .....</b>	<b>12</b>
<b>5.2</b>	<b>Change evaluation .....</b>	<b>12</b>
<b>5.2.1</b>	<b>Identify changes .....</b>	<b>12</b>
<b>5.2.2</b>	<b>Risk evaluation .....</b>	<b>13</b>
<b>5.2.3</b>	<b>Guidance for change evaluation .....</b>	<b>13</b>
<b>5.2.4</b>	<b>Pre-market .....</b>	<b>14</b>
<b>5.3</b>	<b>Interactions with region-specific regulatory authorities -- Post-commercialization .....</b>	<b>14</b>
	<b>Bibliography .....</b>	<b>22</b>